---
title: "Hyphens Pharma International Limited (1J5.SG)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/1J5.SG.md"
symbol: "1J5.SG"
name: "Hyphens Pharma International Limited"
industry: "Pharmaceuticals"
datetime: "2026-03-14T09:45:46.795Z"
locales:
  - [en](https://longbridge.com/en/quote/1J5.SG.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/1J5.SG.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/1J5.SG.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/1J5.SG.md) | [繁體中文](https://longbridge.com/zh-HK/quote/1J5.SG.md)


# Hyphens Pharma International Limited (1J5.SG)

## Company Overview

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products in ASEAN countries. This segment focuses on various therapeutic areas, such as dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, psychiatry, family medicine, and medical aesthetics.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | SG Market |
| Website | [www.hyphensgroup.com](https://www.hyphensgroup.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-14T04:30:15.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 4 / 6 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -9.24% |  |
| Net Profit YoY | -42.67% |  |
| P/B Ratio | 1.37 |  |
| Dividend Ratio | 4.84% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 95741466.43 |  |
| Revenue | 177351748.11 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.29% | B |
| Profit Margin | 3.29% | C |
| Gross Margin | 39.82% | B |
| Revenue YoY | -9.24% | D |
| Net Profit YoY | -42.67% | D |
| Total Assets YoY | -8.95% | E |
| Net Assets YoY | -2.55% | D |
| Cash Flow Margin | 3035.03% | A |
| OCF YoY | -9.24% | D |
| Turnover | 1.37 | A |
| Gearing Ratio | 41.29% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hyphens Pharma International Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-9.24%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-42.67%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.37",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "4.84%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "95741466.43",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "177351748.11",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.29%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "3.29%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "39.82%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-9.24%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-42.67%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-8.95%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-2.55%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "3035.03%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-9.24%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "1.37",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "41.29%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 16.38 | 3/6 | 16.73 | 16.02 | 8.94 |
| PB | 1.37 | 3/6 | 1.66 | 1.56 | 1.29 |
| PS (TTM) | 0.54 | 1/6 | 0.58 | 0.56 | 0.47 |
| Dividend Yield | 4.84% | 2/6 | 4.69% | 4.41% | 4.05% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | CMS (8A8.SG) | B | C | C | A | C | B |
| 02 | Haw Par (H02.SG) | B | D | E | A | D | C |
| 03 | TJ DaRenTang USD (T14.SG) | A | D | C | B | D | C |
| 04 | Hyphens Pharma (1J5.SG) | B | D | A | C | C | C |
| 05 | IX Biopharma (42C.SG) | E | B | C | D | D | D |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-04T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.31 |
| Highest Target | 0.43 |
| Lowest Target | 0.40 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/1J5.SG/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/1J5.SG/norm.md)
- [Related News](https://longbridge.com/en/quote/1J5.SG/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**